Bingwen Zou

3.6k total citations · 2 hit papers
95 papers, 2.1k citations indexed

About

Bingwen Zou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bingwen Zou has authored 95 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Bingwen Zou's work include Nanoplatforms for cancer theranostics (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Treatments and Mutations (14 papers). Bingwen Zou is often cited by papers focused on Nanoplatforms for cancer theranostics (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Treatments and Mutations (14 papers). Bingwen Zou collaborates with scholars based in China, Australia and United States. Bingwen Zou's co-authors include Canhua Huang, Na Xie, Wei Gao, Lu Zhang, Xiaobo Zhou, Guobo Shen, Peter Huber, Changlong Li, Gang Guo and Rangrang Fan and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Applied Physics Letters.

In The Last Decade

Bingwen Zou

89 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

2020 608 citations Na Xie, Lu Zhang et al. Signal Transduction and Targeted Therapy profile →
Roles of MXenes in biomedical applications: recent developments and prospects

2023 136 citations Rangrang Fan, Bingwen Zou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bingwen Zou China	24	740	440	409	384	270	95	2.1k
Guan Jiang China	20	804 1.1×	502 1.1×	301 0.7×	339 0.9×	275 1.0×	52	2.0k
Yongchuan Deng China	24	914 1.2×	498 1.1×	311 0.8×	498 1.3×	427 1.6×	53	2.4k
Yunxiang Zhou China	20	784 1.1×	468 1.1×	238 0.6×	276 0.7×	222 0.8×	43	2.1k
Wei Shi China	28	887 1.2×	556 1.3×	263 0.6×	440 1.1×	242 0.9×	136	2.8k
Mariusz Kaczmarek Poland	23	730 1.0×	287 0.7×	251 0.6×	401 1.0×	230 0.9×	119	2.1k
Haohuan Li China	27	834 1.1×	343 0.8×	253 0.6×	205 0.5×	362 1.3×	140	2.1k
Moshe Schaffer Germany	22	702 0.9×	396 0.9×	531 1.3×	360 0.9×	245 0.9×	63	2.1k
Xiaoxuan Xu China	29	1.1k 1.5×	673 1.5×	229 0.6×	253 0.7×	281 1.0×	103	2.8k
Ana Margarida Abrantes Portugal	30	782 1.1×	294 0.7×	387 0.9×	613 1.6×	414 1.5×	165	3.1k
Haitao Zhu China	28	1.2k 1.7×	295 0.7×	320 0.8×	447 1.2×	533 2.0×	76	2.4k

Countries citing papers authored by Bingwen Zou

Since Specialization

Citations

This map shows the geographic impact of Bingwen Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bingwen Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bingwen Zou more than expected).

Fields of papers citing papers by Bingwen Zou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bingwen Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bingwen Zou. The network helps show where Bingwen Zou may publish in the future.

Co-authorship network of co-authors of Bingwen Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Bingwen Zou. A scholar is included among the top collaborators of Bingwen Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bingwen Zou. Bingwen Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mu, Min, Bo Chen, Nianyong Chen, et al.. (2025). A fusion of oncolytic viruses and bispecific T-cell engagers for triple negative breast cancer immunotherapy. Chemical Engineering Journal. 508. 160853–160853. 1 indexed citations

Mu, Min, Guoqing Wang, Hui Li, et al.. (2025). Decomposable STING nanoagonist-amplified oncolytic virotherapy through remodeling the immunosuppressive microenvironment of triple-negative breast cancer. Journal of Materials Chemistry B. 13(11). 3685–3699. 2 indexed citations

Yao, Zhuoran, Min Tang, Ying Jin, et al.. (2025). Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor–Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations. Journal of Thoracic Oncology. 20(10). 1531–1537.

Wang, Wenhui, Li Zhao, Xiaomeng Zhang, et al.. (2025). Investigating factors influencing subjective taste and smell alterations in colorectal cancer patients. Supportive Care in Cancer. 33(3). 205–205.

Zhang, Yi, Zheng Li, Ying Huang, Bingwen Zou, & Yong Xu. (2024). Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis. BMJ Open. 14(1). e073887–e073887. 2 indexed citations

Hu, Binbin, Kejia Zhao, Yu‐Shang Yang, et al.. (2024). Investigating esophageal sarcomatoid carcinoma and its comparison with esophageal squamous cell carcinoma on clinicopathological characteristics, prognosis, and radiomics features: a retrospective study. Frontiers in Oncology. 14. 1398982–1398982. 1 indexed citations

Wang, Lin, Bingwen Zou, Haiyu Zhou, et al.. (2024). Chemoradiotherapy (CRT) Combined with Consolidative Iruplinalkib for ALK/ROS1+ Unresectable Non-Small Cell Lung Cancer (NSCLC): ALK+ Cohort Results from Part 1 of the INNOVATION Study. International Journal of Radiation Oncology*Biology*Physics. 120(2). e76–e77.

Mu, Min, Hui Li, Rangrang Fan, et al.. (2024). Augmented the sensitivity of photothermal-ferroptosis therapy in triple-negative breast cancer through mitochondria-targeted nanoreactor. Journal of Controlled Release. 375. 733–744. 23 indexed citations

Zhang, Yi, et al.. (2024). Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis. Future Oncology. 20(21). 1505–1514. 3 indexed citations

10.

Zhang, Yi, Zheng Li, Ying Huang, Bingwen Zou, & Yong Xu. (2023). Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia. Frontiers in Immunology. 14. 1258786–1258786. 26 indexed citations

11.

Chen, Xianyan, Xuanwei Zhang, Min Wang, et al.. (2023). Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy. Thoracic Cancer. 14(27). 2735–2744. 1 indexed citations

12.

Chen, Xianyan, Yingjie Zhang, Xiaojuan Zhou, et al.. (2023). Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival. Frontiers in Oncology. 13. 1274924–1274924. 2 indexed citations

13.

Zhang, Yingying, Yuan Yang, Yong Xu, et al.. (2023). 1540P Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study. Annals of Oncology. 34. S865–S865. 4 indexed citations

14.

Zhang, Yi, Qiong Li, Zhao Huang, et al.. (2022). Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers. 14(19). 4568–4568. 88 indexed citations

15.

Mu, Min, Haifeng Chen, Rangrang Fan, et al.. (2021). A Tumor-Specific Ferric-Coordinated Epigallocatechin-3-gallate cascade nanoreactor for glioblastoma therapy. Journal of Advanced Research. 34. 29–41. 35 indexed citations

16.

Ye, Qin, Li Zhou, Ping Jin, et al.. (2021). Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer. Frontiers in Pharmacology. 12. 621181–621181. 12 indexed citations

17.

Xie, Na, Lu Zhang, Wei Gao, et al.. (2020). NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy. 5(1). 227–227. 608 indexed citations breakdown →

18.

Perez, Ramon Lopez, Alexander Rühle, Thuy Trinh, et al.. (2019). Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. Stem Cell Research. 40. 101536–101536. 19 indexed citations

19.

Zou, Bingwen, Tao Li, Daiyuan Ma, et al.. (2016). Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients. Medicine. 95(17). e3507–e3507. 18 indexed citations

20.

Huang, Meijuan, Xinxing Zhang, Min Yu, et al.. (2011). Salvage treatment with erlotinib after gefitinib failure in advanced non‐small‐cell lung cancer patients with poor performance status: A matched‐pair case–control study. Thoracic Cancer. 3(1). 27–33. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact